FDA Approves Nivolumab with Ipilimumab for Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer By Ogkologos - May 9, 2025 361 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CHECKMATE-8HW study Source RELATED ARTICLESMORE FROM AUTHOR No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe MOST POPULAR NICE doesn’t recommend olaparib for patients with certain prostate cancers September 13, 2022 The EPA’s Limitations On This Toxic Pesticide Put Children At Risk... February 5, 2021 10 Ways to Brave Cancer Treatment: Tips from a Survivor September 27, 2022 Adding Lenvatinib to Pembrolizumab Does Not Provide Additional Benefit in Patients... September 10, 2025 Load more HOT NEWS Poziotinib Shows Promising Antitumour Activity in Patients with HER2 Exon 20... Researchers Discover New Way to Prevent Hair Loss During Chemotherapy Treatment seven Interesting Facts about Malignant tumors Boy Between the sheets Efficacy of Dabrafenib Plus Trametinib in First-Line Treatment for Children and...
